The global tuberculosis drugs/therapeutics (TB) market size is
expected to reach USD 1.38 billion by 2025, according to a new report by Grand
View Research, Inc., registering a CAGR of 5.2% during the forecast period.
Rising prevalence of Multidrug Resistant (MDR) tuberculosis and
HIV-tuberculosis co-infection is likely to drive the market during the forecast
period. According to WHO, in 2017, the annual incidence of tuberculosis (TB) in
India was 2.8 million cases, with an estimated 147,000 multi-drug resistant
cases. India has the second highest estimation of HIV-TB co-infection cases per
year, i.e., 87,000.
The TB drugs market is expected to witness
high growth in the coming years due to development of shorter-regimen drug
treatments and availability of private and public funding. The Nix-TB trial
currently being conducted by TB Alliance in conjunction with Janssen
Pharmaceuticals involves a combination of drugs, pretomanid, linezolid, and
bedaquiline, which promises a cure for Extensively Drug Resistant (XDR) form of
the disease within 6-9 months.
Apart from competitive dynamics, license
agreements among players are providing opportunities for emerging drug
manufacturers to grow in this space. In September 2015, Dishman Group received
a license agreement from Janssen Pharmaceutica NV, subsidiary of Johnson &
Johnson Services, LLC to produce the active pharmaceutical ingredient (API) for
the drug Sirturo (bedaquiline), intended for MDR TB treatment. Dishman, apart
from being an API supplier for Janssen’s novel drug, is now listed as a
licensed API manufacturer with the EMA, USFDA, and several Asian regulatory
authorities.
Full Research Report On tuberculosis drugs/therapeutics
(TB) market Analysis:
https://www.grandviewresearch.com/industry-analysis/tuberculosis-tb-drugs-therapeutics-market
https://www.grandviewresearch.com/industry-analysis/tuberculosis-tb-drugs-therapeutics-market
Further key findings from the report suggest:
·
Collaborative efforts among
international organizations and pharmaceutical players are spurring drug
development and treatment access, which is expected to propel the growth of the
tuberculosis drugs market
·
In March 2015, a collaboration
between the United States Agency for International Development (USAID) and the
Janssen Global Services, LLC was undertaken to provide the drug bedaquiline
free of cost to eligible MDR-tuberculosis patients
·
Based on disease type, the
active tuberculosis drugs segment accounted for the largest share of 87.3% in
2016. If undiagnosed, latent tuberculosis has the potential to transform to the
active form, which has led countries in Europe and North America to focus on
early diagnosis and preventive measures
·
Based on therapy type,
second-line therapy drugs led the market with a share of 60.4% in 2016. Rising
incidence and higher treatment cost structure of MDR tuberculosis, coupled with
increasing treatment access, is spurring market growth
·
Regionally, Asia Pacific held a
major market share and is expected to retain its dominance during the forecast
period due to high disease incidence and gradual improvement in patient
medication adherence rates
·
Europe is likely to witness
significant growth over the next decade due to high MDR-TB burden, along with
improved focus on LTBI treatment drugs
·
Some of the key players in the
tuberculosis drugs market are Johnson & Johnson (J&J) Services, Lupin,
Pfizer, Novartis AG, Macleods Pharmaceuticals Limited, and Otsuka
Pharmaceutical Co., Ltd.
View More Reports Of This Category By Grand View Research
At: https://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the
global tuberculosis drugs market based on disease type, therapy, and region:
Tuberculosis Drugs Disease Type (Revenue, USD Million,
2014 - 2025)
·
Active TB
·
Latent TB
Tuberculosis Drugs Therapy (Revenue, USD Million, 2014 -
2025)
·
First-Line Therapy
·
Second-Line Therapy
Tuberculosis Drugs Regional Outlook (Revenue, USD
Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o U.K.
o France
o Germany
·
Asia Pacific
o China
o India
o Philippines
·
Latin America
o Brazil
o Mexico
·
Africa
o South Africa
o Nigeria
Access Full Press Release of this Report:
https://www.grandviewresearch.com/press-release/global-tuberculosis-tb-drugs-therapeutics-market
https://www.grandviewresearch.com/press-release/global-tuberculosis-tb-drugs-therapeutics-market
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/